Ribonucleic Acid (RNA) Microarray Global Market Report 2026

Ribonucleic acid (RNA) microarray is a high-throughput molecular biology technology designed to analyze the expression levels of thousands of RNA transcripts simultaneously within a biological sample. It enables the identification, measurement, and comparative evaluation of gene expression profiles by hybridizing labeled RNA or complementary DNA (cDNA) molecules with specific probes fixed onto a solid surface.

The primary product types of ribonucleic acid (RNA) microarray include consumables, instruments, software, and accessories. Consumables refer to materials and supplies utilized in RNA microarray experiments for the detection and analysis of gene expression patterns. These products utilize technologies such as hybridization-based microarrays, sequencing-based microarrays, and other technologies. The major applications include genomic research, clinical diagnostics, pharmaceuticals and biotechnology, and agricultural biotechnology, and they are utilized by various end-users such as biotechnology companies, pharmaceutical companies, academic and research institutes, diagnostic laboratories, and contract research organizations.

Tariffs are influencing the ribonucleic acid (RNA) microarray market by increasing the cost of imported consumables, instruments, and high-precision scanning systems required for gene expression analysis workflows. This is creating cost pressures for academic research institutes, biotechnology companies, and diagnostic laboratories, particularly in import-dependent regions such as Asia-Pacific and Latin America. Instrument-intensive segments, including microarray scanners and hybridization systems, are the most affected due to their reliance on globally sourced optical, electronic, and photonic components. However, tariffs are encouraging the localization of manufacturing, strengthening regional supply chains, and accelerating investment in domestic genomics infrastructure, gradually improving market resilience and reducing long-term dependence on imports.

The ribonucleic acid (rna) microarray market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna) microarray market statistics, including ribonucleic acid (rna) microarray industry global market size, regional shares, competitors with a ribonucleic acid (rna) microarray market share, detailed ribonucleic acid (rna) microarray market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) microarray industry. This ribonucleic acid (rna) microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ribonucleic acid (RNA) microarray market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.77 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growth in genomic research and gene expression studies, development of dna and rna hybridization based microarray platforms, increasing adoption of clinical diagnostics using gene expression profiling, expansion of pharmaceutical research using transcriptomic data, rising demand for high throughput molecular biology techniques.

The ribonucleic acid (RNA) microarray market size is expected to see strong growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to integration of AI driven gene expression interpretation tools, increasing demand for personalized medicine and biomarker discovery, expansion of multi omics and systems biology research, rising adoption of automated and high throughput microarray platforms, growth in cloud enabled genomic data analytics and storage solutions. Major trends in the forecast period include integration of AI powered gene expression analysis platforms for large scale rna microarray data interpretation, increasing adoption of cloud based microarray data storage and bioinformatics pipelines, expansion of high density microarray chips for multi transcriptome profiling, growing use of automated microarray scanning and hybridization systems, rising demand for precision medicine driven gene expression profiling using rna microarrays.

The growing adoption of personalized medicine is expected to drive the expansion of the ribonucleic acid (RNA) microarray market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatments and clinical decisions to individual patients based on their genetic characteristics, lifestyle, and environmental influences. The adoption of personalized medicine is increasing due to advancements in genomics and biotechnology, which enable more accurate diagnoses and targeted therapies based on a patient's unique genetic profile. Ribonucleic acid (RNA) microarrays support personalized medicine by simultaneously analyzing the expression levels of thousands of genes, enabling clinicians to identify disease-specific molecular signatures and customize treatments according to an individual's biological profile for more precise and effective therapy selection. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to 6 approvals in 2022, representing an increase of 10 personalized treatment approvals. Therefore, the growing adoption of personalized medicine is driving the growth of the ribonucleic acid (RNA) microarray market.

The increasing prevalence of cancer is expected to propel the growth of the ribonucleic acid (RNA) microarray market going forward. Cancer prevalence refers to the total number of individuals living with cancer within a defined population during a specific period or at a particular point in time. The increasing prevalence of cancer is mainly attributed to the aging global population, as older individuals are more likely to accumulate genetic mutations and develop malignant diseases over time. Ribonucleic acid (RNA) microarrays contribute to cancer research and clinical oncology by enabling high-throughput gene expression profiling, helping researchers and clinicians identify tumor-specific biomarkers, better understand disease mechanisms, and assess treatment responses at the transcriptomic level. For instance, in January 2023, according to the American Cancer Society, a US-based cancer surveillance and epidemiology organization headquartered in Atlanta, 1,958,310 new cancer cases were reported in 2023, compared to 1,918,030 cases in 2022, reflecting an increase of approximately 40,280 new cases year over year. Therefore, the increasing prevalence of cancer is driving the growth of the ribonucleic acid (RNA) microarray market.

The increasing government funding for biotechnology research initiatives is expected to propel the growth of the ribonucleic acid (RNA) microarray market going forward. Biotechnology research initiatives are structured programs and projects supported by governments, research institutions, or private organizations to advance the development and application of biological and molecular technologies across healthcare, agriculture, and industrial sectors. Government investment in biotechnology research is increasing due to the growing need to address complex health conditions such as cancer and genetic disorders, which require advanced scientific research and innovative technologies for improved diagnosis, treatment, and prevention. Government funding for ribonucleic acid (RNA) microarray research supports advanced genomic studies, facilitates the development of high-throughput gene expression technologies, enhances cancer diagnostics and biomarker discovery, and accelerates the translation of molecular research into clinical practice. For instance, in May 2023, according to the Earlham Institute (EI), a UK-based research institute, it received $39.7 million (£31.4 million) from the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), to support a five-year program focused on advancing research, developing new technologies, and fostering innovation and impact. Therefore, the increasing government funding for biotechnology research initiatives is driving the growth of the ribonucleic acid (RNA) microarray market.

Major companies operating in the ribonucleic acid (RNA) microarray market report are Thermo Fisher Scientific Inc., LGC Limited, Merck KGaA, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Arraystar Inc., Takara Bio Inc., Macrogen Inc., CapitalBio Technology, Genotypic Technology Pvt Ltd., CD Genomics, Phalanx Biotech Group, LC Sciences, Enzo Biochem Inc., Oxford Gene Technology, Bioneer Corporation, Savyon Diagnostics

North America was the dominating region in the ribonucleic acid (RNA) microarray market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) microarray market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA) microarray market consists of revenues earned by entities by providing services such as microarray assay design, sample preparation, gene expression profiling, data analysis and interpretation, bioinformatics support, and laboratory testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) microarray market also includes sales of microarray chips or plates, microarray scanners, hybridization stations, labeling kits, reagents, and probes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid (RNA) Microarray Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ribonucleic acid (rna) microarray market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid (rna) microarray ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna) microarray market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Consumables; Instruments; Software; Accessories
• 2) By Technology: Hybridization Based Microarrays; Sequencing Based Microarrays; Other Technologies
• 3) By Application: Genomic Research; Clinical Diagnostics; Pharmaceuticals And Biotechnology; Agricultural Biotechnology
• 4) By End User: Biotechnology Companies; Pharmaceutical Companies; Academic And Research Institutes; Diagnostic Laboratories; Contract Research Organizations
• Subsegments:
• 1) By Consumables: Hybridization Probes And Oligonucleotide Arrays; Microarray Slides And Chips; Labeling And Hybridization Reagents; Wash Buffers And Detection Kits; Sample Preparation Consumables
• 2) By Instruments: Ribonucleic Acid Microarray Scanners; Hybridization Stations; Microarray Imaging Systems; Automated Sample Processing Instruments; Microarray Spotting Systems
• 3) By Software: Gene Expression Analysis Software; Data Normalization And Processing Software; Bioinformatics Interpretation Software; Visualization And Reporting Software; Statistical Analysis Software
• 4) By Accessories: Microarray Storage Boxes; Hybridization Chambers; Pipette Tips And Consumable Tools; Calibration And Maintenance Accessories; Slide Carriers And Handling Tools
• Companies Mentioned: Thermo Fisher Scientific Inc.; LGC Limited; Merck KGaA; Danaher Corporation; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Revvity Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Arraystar Inc.; Takara Bio Inc.; Macrogen Inc.; CapitalBio Technology; Genotypic Technology Pvt Ltd.; CD Genomics; Phalanx Biotech Group; LC Sciences; Enzo Biochem Inc.; Oxford Gene Technology; Bioneer Corporation; Savyon Diagnostics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.